Stockscreener 앱 받기
8.60
3.24%
0.27
시장 영업 전:
8.58
-0.02
-0.23%
전일 마감가:
$8.33
열려 있는:
$8.33
하루 거래량:
1.36M
Relative Volume:
0.75
시가총액:
$1.57B
수익:
$314.85M
순이익/손실:
$12.01M
주가수익비율:
131.30
EPS:
0.0655
순현금흐름:
$47.52M
1주 성능:
+8.45%
1개월 성능:
+3.86%
6개월 성능:
+26.10%
1년 성능:
+17.81%
1일 변동 폭
$8.25
$8.67
1주일 범위
$7.80
$8.70
52주 변동 폭
$5.25
$10.08
Xeris Biopharma Holdings Inc Stock (XERS) Company Profile
명칭
Xeris Biopharma Holdings Inc
전화
844-445-5704
주소
1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL
Compare XERS vs TAK, TEVA, HLN, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
XERS
Xeris Biopharma Holdings Inc
|
8.60 | 1.55B | 314.85M | 12.01M | 47.52M | 0.0655 |
TAK
Takeda Pharmaceutical Co Adr
|
17.63 | 55.60B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.77 | 42.81B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.70 | 43.16B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
73.79 | 30.39B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
499.73 | 21.95B | 3.17B | 1.29B | 1.01B | 27.09 |
Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-09 | 개시 | Barclays | Overweight |
| 2025-08-12 | 재개 | H.C. Wainwright | Buy |
| 2024-11-11 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-03-28 | 개시 | Oppenheimer | Outperform |
| 2023-08-28 | 개시 | Craig Hallum | Buy |
| 2022-10-21 | 개시 | Jefferies | Buy |
| 2022-04-28 | 개시 | Craig Hallum | Buy |
| 2021-11-17 | 개시 | SVB Leerink | Outperform |
| 2021-10-29 | 개시 | H.C. Wainwright | Buy |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2020-02-18 | 개시 | Piper Sandler | Overweight |
| 2018-07-16 | 개시 | Jefferies | Buy |
| 2018-07-16 | 개시 | Leerink Partners | Outperform |
| 2018-07-16 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Xeris Biopharma Holdings Inc 주식(XERS)의 최신 뉴스
Walleye Capital LLC Invests $4.84 Million in Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
Why Xeris Biopharma Holdings (XERS) Is Up 8.4% After Tightening 2026 Revenue Guidance And Advancing XP-8121 - Yahoo Finance
Xeris Biopharma Holdings (XERS) Posts Record Q2 Revenue, Is It Still A Bargain? - Yahoo Finance
XERS|Xeris Biopharma Holdings Inc|Price:8.322|Chg%:-0.168 - TradingKey
Mission Produce And Two Other Stocks Estimated To Be Trading Below Intrinsic Value - simplywall.st
Xeris Biopharma (NASDAQ:XERS) Insider Sells $42,500.00 in Stock - MarketBeat
Xeris Biopharma (XERS) insider Steven Pieper plans Rule 144 sale of 20,000 shares - Stock Titan
HC Wainwright Comments on Xeris Biopharma FY2026 Earnings - MarketBeat
Janus Henderson Group PLC Boosts Stock Holdings in Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
Renaissance Technologies LLC Cuts Stock Position in Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
Xeris Biopharma Holdings Inc (XERS) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
HC Wainwright Expects Weaker Earnings for Xeris Biopharma - MarketBeat
Xeris Biopharma Holdings, Inc. (XERS) options chain – Yahoo Finance - Yahoo Finance Singapore
Sei Investments Co. Has $3.36 Million Stake in Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
Xeris Biopharma (XERS) Stock Jumps On Record Revenue Despite Wider Losses - Sahm
Xeris Biopharma (NASDAQ:XERS) Downgraded to "Buy" Rating by Wall Street Zen - MarketBeat
Xeris Biopharma Q2 Earnings Call Highlights - MarketBeat
Xeris Biopharma Holdings Inc (XERS) Stock News Today - TradingKey
Xeris Biopharma Holdings, Inc. (XERS) Stock Analysis: A Lucrative 53% Upside Potential for Investors - DirectorsTalk Interviews
Xeris Biopharma (NASDAQ:XERS) Issues Earnings Results, Misses Expectations By $0.19 EPS - MarketBeat
Xeris Biopharma Holdings Inc (XERS) (Q2 2026) Earnings Call High - GuruFocus
XERS Looks 53.1% Overvalued on GF Value™ as Insider Selling Pers - GuruFocus
Xeris Biopharma Holdings, Inc. 2026: Revenue $92.1M, EPS ($0.18) — 10-Q Summary - TradingView
Xeris raises outlook despite posting $31.1 million loss - Crain's Chicago Business
Xeris Biopharma (NASDAQ:XERS) Shares Gap Down Following Weak Earnings - MarketBeat
Is Xeris Biopharma Holdings Inc (XERS) Still a Smart Investment? - GuruFocus
Xeris Biopharma Holdings, Inc. Provides Revenue Guidance for the Full Year 2026 - marketscreener.com
Earnings call transcript: Xeris Biopharma posts Q2 2026 revenue beat, EPS miss - Investing.com
Xeris Biopharma Holdings, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Compared to Estimates, Xeris Biopharma (XERS) Q2 Earnings: A Look at Key Metrics - Yahoo Finance
(XERS) Xeris Biopharma Expects Full Year 2026 Revenue Range $385M$390M, vs. FactSet Est of $385.9M - marketscreener.com
Q2 2026 Xeris Biopharma Holdings Inc Earnings Call Transcript - GuruFocus
Xeris Biopharma: Q2 Earnings Snapshot - marketscreener.com
XERS: Q2 2026 revenue grew 34% year-over-year, driven by Recorlev, with improved margins and strong outlook - TradingView
Xeris Biopharma Reports Second Quarter 2026 Financial Results - Business Wire
Xeris Q2 FY26 net loss widens to $31.1 million; revenue rises 29% to $92.1 million - Bitget
Xeris Biopharma (XERS) Insider Beth Hecht Sells 16,666 Shares - GuruFocus
Xeris Biopharma (NASDAQ:XERS) Insider Kevin Mcculloch Sells 15,000 Shares of Stock - MarketBeat
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Vanguard Capital Management (XERS) discloses 8.64M-share, 5% holding in Xeris - Stock Titan
Xeris Biopharma Holdings (XERS) Stock Analysis: Promising 34% Upside Potential Amidst Robust Growth - DirectorsTalk Interviews
XERS Q2'26 Earnings: revenue estimate is 90.12M USD - TradingView
Rice Hall James & Associates LLC Acquires Shares of 251,066 Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
Xeris Biopharma Holdings Inc (XERS) Cash Flow - TradingKey
Xeris Biopharma Holdings Inc (XERS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Xeris Biopharma Holdings Inc (XERS) Income Statement - TradingKey
Xeris Biopharma Holdings Inc (XERS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Xeris Biopharma Holdings Inc (XERS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Xeris Biopharma Holdings Inc (XERS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
XERS|Xeris Biopharma Holdings Inc|Price:8.200|Chg%:-0.120 - TradingKey
Xeris Biopharma Holdings Inc (XERS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Xeris Biopharma Holdings Inc (XERS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.79%
5.15%
자본화:
|
볼륨(24시간):